Drug
Ponatinib clinical trials
Also written AP24534 and Iclusig.
- studies test it
- 57
- open now
- 11
- in phase 3
- 5
- first study started
- 2008
Keep track of what changes. Save the ponatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
57 studies that test it; most in 2013 (7)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 7 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 6 |
| 2020 | 6 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 50
- Phase 3
- 5
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 45
M.D. Anderson Cancer Center (9) · Ariad Pharmaceuticals (6) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · Takeda (3) · Versailles Hospital (3) · Dana-Farber Cancer Institute (2) · University of Chicago (2) · OHSU Knight Cancer Institute (2)
Often tested with
Tested in the same studies.
Blinatumomab (5) · Venetoclax (4) · Dasatinib (4) · Imatinib (3) · Cobimetinib (3) · Cytarabine (3) · Erlotinib (2) · Ado-Trastuzumab Emtansine (2)
Studies
Open first, then newest update. How each study uses ponatinib is read from its arms, and is right about nine times in ten.
Testing it · 57
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT03739814Written as Ponatinib
- Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingPhase 1/2Incyte Biosciences International SàrlNCT03934372Written as Ponatinib
- Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibRecruitingPhase 2M.D. Anderson Cancer CenterNCT01746836Written as Ponatinib Hydrochloride
- Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/LymphomaRecruitingPhase 2University of WashingtonNCT07224100Written as Ponatinib
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Ponatinib
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingPhase 2University of ChicagoNCT04747912Written as Ponatinib
- Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03263572Written as Ponatinib
- A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)RecruitingPhase 1/2University of ChicagoNCT06207123Written as Ponatinib
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingPhase 2Goethe UniversityNCT06061094Written as Ponatinib
- Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid LeukemiaNot yet recruitingPhase 2Associazione Italiana Pazienti Leucemia Mieloide CronicaNCT04709731Written as Ponatinib 15mg QD
- Study in Adult Ph-positive ALLNot yet recruitingPhase 2Cardiff UniversityNCT04688983Written as Ponatinib
- The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationCompletedPhase 2Otsuka Beijing Research InstituteNCT04233346Written as Ponatinib 30mg OD
- Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)CompletedPhase 2Fundacion CRIS de Investigación para Vencer el CáncerNCT04160546Written as Ponatinib 15 MG
- Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT01424982Written as Ponatinib
- Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03147612Written as Ponatinib
- Ponatinib for FLT3-ITD Acute Myelogenous LeukemiaCompletedPhase 1/2Versailles HospitalNCT02428543Written as Ponatinib and Cytarabine
- PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISISCompletedPhase 2Versailles HospitalNCT03895671Written as Ponatinib
- Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT04188405Written as Ponatinib
- A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaTerminatedPhase 2M.D. Anderson Cancer CenterNCT05268003Written as Ponatinib
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of DosesCompletedPhase 2TakedaNCT02467270Written as Ponatinib
See all 57 studies that test ponatinib →
Given in every arm · 2 — ponatinib is usual care beside what is tested
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04530565Written as Ponatinib Hydrochloride
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedPhase 1OHSU Knight Cancer InstituteNCT02779283Written as Ponatinib Hydrochloride
Codes
What other systems call ponatinib · ClinicalTrials.gg INT005531
- MeSH (NLM) C545373ponatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4340891KFSPONATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1364347Confirmed FDA, Wikidata
- Wikidata Q198728ponatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95777PonatinibOne source FDA
- DrugBank DB08901One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545373 | ponatinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4340891KFS | PONATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1364347 | — | Confirmed FDA, Wikidata |
| Wikidata | Q198728 | ponatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95777 | Ponatinib | One source FDA |
| DrugBank | DB08901 | — | One source Wikidata |
Also registered as ponatinib hydrochloride (UNII 96R6PU3D8J · RxNorm 1364953).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.